Endocervical prostaglandin E2 gel for preinduction cervical softening

M. Thiery, J. M. Decoster, W. Parewijck, M. L. Noah, R. Derom, H. Van Kets, P. Defoort, W. Aertsens, G. Debruyne, Koenraad De Geest, F. Vandekerckhove

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

A single, endocervical application of a new commercial preparation of prostaglandin E2 (PGE2) gel, 0.5 mg of PGE2 in 2.5 ml (3g), was evaluated for preinduction cervical softening. Safety and efficacy were assessed in a comparison with a 2.0 mg PGE2 vaginal tablet and placebo in normal nulliparous women at term, with low Bishop scores. Treatment was administered in randomized, double blind fashion. Overall success, defined as a progression in Bishop score of at least 3 points within 12 hours, was achieved in 22/40 (55 %) of the gel group, 15/41 (37 %) in the tablet treated women, and 8/40 (20 %) in those receiving placebo. Od interest was the observation that of women with very unfavorable induction features (Bishop score 0-2), the cervical gel treatment resulted in a 6/8 (75 %) success rate compared with 2/13 (15 %) success for the vaginal tablet and 0/7 (0 %) for placebo. In as much as a very low incidence of side effects accompanied this treatment scheme, expanded multi-center testing is recommended.

Original languageEnglish (US)
Pages (from-to)429-439
Number of pages11
JournalProstaglandins
Volume27
Issue number3
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Dinoprostone
Foams and Jellies Vaginal Creams
Gels
Placebos
Tablets
Therapeutics
Safety
Incidence
Testing

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Thiery, M., Decoster, J. M., Parewijck, W., Noah, M. L., Derom, R., Van Kets, H., ... Vandekerckhove, F. (1984). Endocervical prostaglandin E2 gel for preinduction cervical softening. Prostaglandins, 27(3), 429-439. https://doi.org/10.1016/0090-6980(84)90201-6

Endocervical prostaglandin E2 gel for preinduction cervical softening. / Thiery, M.; Decoster, J. M.; Parewijck, W.; Noah, M. L.; Derom, R.; Van Kets, H.; Defoort, P.; Aertsens, W.; Debruyne, G.; De Geest, Koenraad; Vandekerckhove, F.

In: Prostaglandins, Vol. 27, No. 3, 1984, p. 429-439.

Research output: Contribution to journalArticle

Thiery, M, Decoster, JM, Parewijck, W, Noah, ML, Derom, R, Van Kets, H, Defoort, P, Aertsens, W, Debruyne, G, De Geest, K & Vandekerckhove, F 1984, 'Endocervical prostaglandin E2 gel for preinduction cervical softening', Prostaglandins, vol. 27, no. 3, pp. 429-439. https://doi.org/10.1016/0090-6980(84)90201-6
Thiery M, Decoster JM, Parewijck W, Noah ML, Derom R, Van Kets H et al. Endocervical prostaglandin E2 gel for preinduction cervical softening. Prostaglandins. 1984;27(3):429-439. https://doi.org/10.1016/0090-6980(84)90201-6
Thiery, M. ; Decoster, J. M. ; Parewijck, W. ; Noah, M. L. ; Derom, R. ; Van Kets, H. ; Defoort, P. ; Aertsens, W. ; Debruyne, G. ; De Geest, Koenraad ; Vandekerckhove, F. / Endocervical prostaglandin E2 gel for preinduction cervical softening. In: Prostaglandins. 1984 ; Vol. 27, No. 3. pp. 429-439.
@article{2c78768957354966b9c8c73041f14080,
title = "Endocervical prostaglandin E2 gel for preinduction cervical softening",
abstract = "A single, endocervical application of a new commercial preparation of prostaglandin E2 (PGE2) gel, 0.5 mg of PGE2 in 2.5 ml (3g), was evaluated for preinduction cervical softening. Safety and efficacy were assessed in a comparison with a 2.0 mg PGE2 vaginal tablet and placebo in normal nulliparous women at term, with low Bishop scores. Treatment was administered in randomized, double blind fashion. Overall success, defined as a progression in Bishop score of at least 3 points within 12 hours, was achieved in 22/40 (55 {\%}) of the gel group, 15/41 (37 {\%}) in the tablet treated women, and 8/40 (20 {\%}) in those receiving placebo. Od interest was the observation that of women with very unfavorable induction features (Bishop score 0-2), the cervical gel treatment resulted in a 6/8 (75 {\%}) success rate compared with 2/13 (15 {\%}) success for the vaginal tablet and 0/7 (0 {\%}) for placebo. In as much as a very low incidence of side effects accompanied this treatment scheme, expanded multi-center testing is recommended.",
author = "M. Thiery and Decoster, {J. M.} and W. Parewijck and Noah, {M. L.} and R. Derom and {Van Kets}, H. and P. Defoort and W. Aertsens and G. Debruyne and {De Geest}, Koenraad and F. Vandekerckhove",
year = "1984",
doi = "10.1016/0090-6980(84)90201-6",
language = "English (US)",
volume = "27",
pages = "429--439",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Endocervical prostaglandin E2 gel for preinduction cervical softening

AU - Thiery, M.

AU - Decoster, J. M.

AU - Parewijck, W.

AU - Noah, M. L.

AU - Derom, R.

AU - Van Kets, H.

AU - Defoort, P.

AU - Aertsens, W.

AU - Debruyne, G.

AU - De Geest, Koenraad

AU - Vandekerckhove, F.

PY - 1984

Y1 - 1984

N2 - A single, endocervical application of a new commercial preparation of prostaglandin E2 (PGE2) gel, 0.5 mg of PGE2 in 2.5 ml (3g), was evaluated for preinduction cervical softening. Safety and efficacy were assessed in a comparison with a 2.0 mg PGE2 vaginal tablet and placebo in normal nulliparous women at term, with low Bishop scores. Treatment was administered in randomized, double blind fashion. Overall success, defined as a progression in Bishop score of at least 3 points within 12 hours, was achieved in 22/40 (55 %) of the gel group, 15/41 (37 %) in the tablet treated women, and 8/40 (20 %) in those receiving placebo. Od interest was the observation that of women with very unfavorable induction features (Bishop score 0-2), the cervical gel treatment resulted in a 6/8 (75 %) success rate compared with 2/13 (15 %) success for the vaginal tablet and 0/7 (0 %) for placebo. In as much as a very low incidence of side effects accompanied this treatment scheme, expanded multi-center testing is recommended.

AB - A single, endocervical application of a new commercial preparation of prostaglandin E2 (PGE2) gel, 0.5 mg of PGE2 in 2.5 ml (3g), was evaluated for preinduction cervical softening. Safety and efficacy were assessed in a comparison with a 2.0 mg PGE2 vaginal tablet and placebo in normal nulliparous women at term, with low Bishop scores. Treatment was administered in randomized, double blind fashion. Overall success, defined as a progression in Bishop score of at least 3 points within 12 hours, was achieved in 22/40 (55 %) of the gel group, 15/41 (37 %) in the tablet treated women, and 8/40 (20 %) in those receiving placebo. Od interest was the observation that of women with very unfavorable induction features (Bishop score 0-2), the cervical gel treatment resulted in a 6/8 (75 %) success rate compared with 2/13 (15 %) success for the vaginal tablet and 0/7 (0 %) for placebo. In as much as a very low incidence of side effects accompanied this treatment scheme, expanded multi-center testing is recommended.

UR - http://www.scopus.com/inward/record.url?scp=0021287485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021287485&partnerID=8YFLogxK

U2 - 10.1016/0090-6980(84)90201-6

DO - 10.1016/0090-6980(84)90201-6

M3 - Article

C2 - 6374766

AN - SCOPUS:0021287485

VL - 27

SP - 429

EP - 439

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

IS - 3

ER -